Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape
Drs. McKay and Shore discuss novel agents under investigation and their potential to target androgen receptor signaling and slow metastasis in patients with metastatic and castration-resistant prostate cancer.
EP: 1.Metastatic Prostate Cancer: Background and Patient Prognosis
EP: 2.Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer
EP: 3.Treatment Selection in Metastatic and Castration Resistant Prostate Cancer Optimizing Outcomes and Preserving Patient Quality of Life
EP: 4.Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis
EP: 5.Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer
Now Viewing
EP: 6.Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape
EP: 7.Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer
Related Videos
Related Content
